Acute migraine: Current treatment and emerging therapies

Therapeutics and Clinical Risk Management

Volumn 3, Issue 3, 2007, Pages 449-459

  Kalra, Arun A ^a   Elliott, Debra ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Acute; Migraine; Pathophysiology; Treatment

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ACETYLSALICYLIC ACID; ALMOTRIPTAN; BUTORPHANOL; CHLORPROMAZINE; DIHYDROERGOTAMINE; DIZOCILPINE; ELETRIPTAN; ERGOT DERIVATIVE; ERGOTAMINE; FROVATRIPTAN; KETAMINE; KETOROLAC; LIDOCAINE; MEMANTINE; NARATRIPTAN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROCHLORPERAZINE; RIZATRIPTAN; ROFECOXIB; SEROTONIN; SUMATRIPTAN; TRAMADOL; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID; ZOLMITRIPTAN;

ANALGESIC ACTIVITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY CONSTRICTION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEEDBACK SYSTEM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HALLUCINATION; HUMAN; IMAGERY; MEDITATION; MIGRAINE; MIGRAINE AURA; MONOTHERAPY; NAUSEA; NEUROGENIC INFLAMMATION; NEUROMODULATION; NOCICEPTION; NONHUMAN; PATHOPHYSIOLOGY; RELAXATION TRAINING; REVIEW; SEDATION; SENSITIZATION; SIDE EFFECT; SPREADING CORTICAL DEPRESSION; TRIGEMINAL NERVE; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION; VASODILATATION; VOMITING; YOGA;

EID: 34547706001     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Adelman JU, Adelman RD. 2001. Current options for the prevention and treatment of migraine. Clin Ther, 23:772-88.
2. Amery WK, Waelkens J. 1983. Prevention of the last chance: an alternative pharmacologic treatment of migraine. Headache, 23:37-8.
3. Arulmani U, Maassen VanDenBrink A, Villalón CM, et al. 2004. Calcitonin gene-related peptide and its role in migraine pathophysiology. European Journ Pharm, 500:315-30.
4. Ashkenazi A, Young WB. 2005. The effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine. Headache, 45:350-4.
5. Aurora SK, Ahmad BK, Welch KMA, et al. 1998. Transcranial magnetic stimulation confirms hyperexcitability of occipital cortex in migraine. Neurology, 50:1111-14.
6. Benjamin L, Levy MJ, Lasalandra MP, et al. 2004. Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: a Fos study. Neurobiol Dis, 16:500-5.
7. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. 2000. An association between migraine and cutaneous allodynia. Ann Neurol, 47:614-24.
8. Burstein R, Jakubowski M. 2005a. Unitary hypothesis for multiple triggers of the pain and strain of migraine. J Comp Neurol, 493:9-14.
9. Burstein R, Jakubowski M. 2005b. Implications of multimechanism therapy: when to treat? Neurology, 64(Suppl.2):S16-20
10. Bussone G. 2004. Pathophysiology of migraine. Neurol Sci, 25(Suppl. 3): S239-S241.
11. Cicero TJ, Adams EH, Geller A, et al. 1999. A post marketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend, 57:7-22.
12. Classification and WHO ICD-10 Codes - IHS ICHD-II. 2004. Cephalagia, 24:1-16
13. Dalkara T, Zervas NT, Moskowitz MA. 2006. From spreading depression to the trigeminovascular system. Neurol Sci, 27(Suppl. 2):S86-S90.
14. Damen L, Bruijn JK, Verhagen AP, et al. 2005. Symptomatic Treatment of Migraine in Children: A Systematic Review of Medication Trials. Pediatrics, 116:e295-302.
15. Diener HC, Bussone, de Liano H, et al. 2004. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia, 24:947-54
16. 1B/D agonists) in the acute treatment of migraine. Headache, 44:414-25.
17. Dodick DW, Martin VT, Smith T, et al. 2004. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache, 44 (Suppl 1):S20-30.
18. Dodick DW, Martin VT. 2004. Triptans and CNS side effects: pharmacokinetic and metabolic mechanisms. Cephalagia, 24:417-24
19. Doggrell SA. 2004. New drugs for the prevention and treatment of migraine: topiramate and BIBN 4096 BS. Expert Opin Pharmacother, 5:1837-40
20. Dowson AJ. 2003. Analysis of the Patients Attending a Specialist UK Headache Clinic over a 3-Year Period. Headache, 43:14-18.
21. Drummond P, Lance JW. 1983. External vascular changes and the source of pain in the migraine headache. Ann Neurol, 13:32-37.
22. Edvinson L. 2004. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia, 24:611-22.
23. Edvinson L, Uddman R. 2005. Neurobiology in primary headaches. Brain Res Rev, 48:438-56.
24. Eggers SD. 2006. Migraine-related vertigo: diagnosis and treatment. Curr Neurol Neurosci Rep, 6:106-15.
25. Elkind AH, Satin LZ, Nila A, et al. 2004. Frovatriptan use in migraineurs with or at high risk of coronary artery disease. Headache, 44:403-10.
26. Evans RW, Mannix LK. 2002. Triptans for migraine prodrome. Headache, 42:83-84.
27. Farber L, Haus U, Spath M, et al. 2004. Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol Suppl, 119:2-8.
28. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, 358:1668-75.
29. 1B/D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia, 22:633-58.
30. Friedmann MH, Peterson SJ, Behar CF, et al. 2001. Intraoral chilling versus oral sumatriptan for acute migraine. Heart Dis, 3:357-61.
31. Gargus JJ. 2006. Ion channel functional candidate genes in multigenic neuropsychiatric disease. Biol Psychiatry, 60:177-85.
32. Goadsby PJ. 2005. Migraine pathophysiology. Headache, 45(Suppl.1): S14-S24.
33. Grond S, Sablotzki A. 2004. Clinical pharmacology of tramadol. Clin Pharmacokinet, 43:879-923.
34. Hadjikhani N, Sanchez Del Rio M, Wu O, et al. 2001. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA, 98:4687-92.
35. Heydenreich A. 1988. (Punctate transcutaneous electrical nerve stimulation in migraine therapy) (Article in German). Psychiatr Neurol Med Psychol (Leipz), 40:717-23.
36. Hilaire ML, Cross LB, Eichner SF. 2004. Treatment of migraine headaches with sumatriptan in pregnancy. Ann Pharmacother, 38:1726-30
37. Iovino M, Feifel U, Yong C-L, et al. 2004. Safety, tolerability and pharmacokinetics of BIBN4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia, 24:645-56.
38. Karli N, Zarifoglu M, Calisir N, et al. 2005. Comparison of pre-headache phases and trigger factors of migraine and episodic tension-type headache: do they share similar clinical Pathophysiology? Cephalalgia, 25:444-51.
39. Kaube H, Herzog J, Kaufer T, et al. 2000. Aura in some patients with familial migraine can be stopped by intranasal ketamine. Neurology, 55:139-41.
40. Kelman L. 2004. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache, 44:865-872.
41. Kelman L. 2005. The postdrome of the acute migraine attack. Cephalalgia, 26:214-220.
42. Keskinbora K, Aydinli I. 2006. (An atypical Opioid analgesic: Tramadol.) (Article in Turkish) Agri, 18:5-19.
43. Kirchmann N. 2006. Migraine with aura: new understanding from clinical epidemiologic studies. Curr Opin Neurol, 19:286-93.
44. Kors E, Hann J, Ferrari M. 2003. Migraine genetics. Curr Pain Headache Rep, 7:212-17.
45. Krymchantowski AV, Bigal ME. 2004. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol, 4:10-16.
46. Krymchantowski AV, Bigal ME, Moreira PF. Rizatriptan versus rizatriptan plus trimebutine for the acute treatment of migraine: A double-blind, randomized, cross-over, placebo controlled study. Presented as a poster presentation at the AAN meeting in April 2005 at Miami Beach, Fl.
47. Landy SH. 2004. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series. Headache, 44:762-6.
48. Landy SH, McGinnis JE, McDonald SA. 2005. Pilot study evaluating preference for 3-mg versus 6-mg subcutaneous sumatriptan. Headache, 45:346-9.
49. Lashley KS. 1941. Patterns of cerebral integration indicated by scotomas of migraine. Arch Neurol Psych, 46:331-9.
50. Leão AAP. 1944. Spreading depression of activity in the cerebral cortex. J Neurophysiol, 7:359-90.
51. Leniger T, Pageler L, Stude P, et al. 2005. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache, 45:42-6.
52. Lipton RB, Stewart WF, Diamond S, et al. 2001a. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache, 41:646-57
53. Lipton RB, Diamond S, Reed M, et al. 2001b. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache, 41:638-45.
54. Lipton RB, Scher AI, Kolodner K, et al. 2002. Migraine in the United States - epidemiology and patterns of health care use. Neurology, 58:885-894.
55. Lipton RB, Bigal ME. 2005. Migraine epidemiology, impact, and risk factors for progression. Headache, 45(Suppl. 1):S3-S13
56. Lipton RB, Goldstein J, Baggish JS, et al. 2005. Aspirin is Efficacious for the treatment of acute migraine. Headache, 45:283-92
57. Loder E. 2001. Menstrual migraine. Curr Treat Options Neurol, 3:189-200.
58. Loder E. 2005. Post-marketing experience with an opioid nasal spray for migraine: lessons for the future. Cephalagia, 26:89-97.
59. Luciani R, Carter D, Mannix L, et al. 2000. Prevention of migraine during prodrome with naratriptan. Cephalagia, 20:122-126.
60. Mannix LK, Files JA. 2005. The use of triptans in the management of menstrual migraine. CNS Drugs, 19:951-72.
61. Marcus DA, Scharff L, Turk D, et al. 1997. A double-blind provocative study of chocolate as a trigger of headache. Cephalagia, 17:855-62.
62. Melchart D, Thormaehlen J, Hager S, et al. 2003. Acupuncture versus placebo versus sumatriptan for early treatment of migraine attacks: a randomized controlled trial. J Intern Med, 253:181-8.
63. Mellick LB, Mellick GA. 2004. Treatment of primary headache in the emergency department. Headache, 44:840-1.
64. Morillo LE, Alarcon F, Aranaga N, et al. 2005. Clinical Characteristics and Patterns of Medication Use of Migraineurs in Latin America from 12 Cities in 6 Countries. Headache, 45:118-126.
65. Newman, et al. 2002. Poster presented at: The Diamond Headache Clinical Research and Educational Foundation Meeting, July 16-20, 2002, Lake Buena Vista, FL.
66. Peroutka SJ. 1997. Dopamine and migraine. Neurology, 49:650-656.
67. Pfaffenrath V, Rehm M. 1998. Migraine in pregnancy. What are the safest treatment options? Drug Safety Concepts, 19:383-8.
68. Pryse-Phillips WEM, Dodick DW, Edmeads JG, et al. 1998. Guidelines for the non-pharmacologic management of migraine in clinical practice. CMAJ, 159:47-54.
69. Ramadan NM. 2005. Targeting therapy for migraine: what to treat? Neurology, 64(Suppl.2):S4-S8
70. Reiter PD, Nickisch J, Merritt G. 2005. Efficacy and Tolerability of Intravenous Valproic Acid in Acute Adolescent Migraine. Headache, 45:899-903.
71. Robbins L. 1989. Cryotherapy for headache. Headache, 29:598-600.
72. Romoli M, Allais G, Airola G, et al. 2005. Ear acupuncture in the control of migraine pain: selecting the right acupoints by the "needle-contact test". Neurol Sci, 26 Suppl2:s158-161.
73. Rothrock JF. 2006. Headache toolbox: headache diary. Headache, 46:831-832.
74. Rozen T. 2004. Migraine prodrome: a nose on a face. Lancet, 363:517.
75. Russell MB, Rasmussen BK, Fenger K, et al. 1996. Migraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general population. Cephalalgia, 16:239-245.
76. Sang CN, Ramadan NM, Wallihan RG, et al. 2004. LY293558, a novel AMPA/ GluR5 antagonist, is efficacious and well tolerated in acute migraine. Cephalagia, 24:596-602.
77. Saper JR, 1997. Diagnosis and symptomatic treatment of migraine. Headache, 37(Suppl 1):S1-S14.
78. Schwartz, Tamara H, Karpitski Y, et al. 2002. Intravenous Valproate Sodium in the Treatment of Daily Headache. Headache, 42:519-522.
79. Silberstein SD 1993. Headaches and women: treatment of the pregnant and lactating migraineur. Headache, 33:533-540.
80. Silberstein SD. 2000. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 55:754-62.
81. Silberstein SD, Lipton RB, Goadsby PJ. 2002. Migraine: Diagnosis and treatment. In: Headache in clinical practice, 2nd Edition, Martin Dunitz Ltd, London, United Kingdom, p 76.
82. Silberstein SD. 2004. Migraine pathophysiology and its clinical implications. Cephalalgia, 24(Suppl.2):2-7
83. Stewart WF, Lipton RB & Simon D. 1996. Work-related disability: results from the American Migraine Study. Cephalalgia, 16:215-85
84. Stillman MJ, Zajac D, Rybicki LA. 2004. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. Headache, 44:65-9
85. Ta LE, Dionne RA, Friction JR, et al. 2000. SYM-2081 a kainate receptor antagonist reduces allodynia and hyperalgesia in a freeze injury model of neuropathic pain. Brain Res, 858:106-20.
86. Takeshima T, Nakashima K. 2005. (Genetic análisis of migraine headache: a review) (Article in Japanese) Nipón Rinsho, 63:1727-32.
87. Tepper SJ, Rappaport A, Sheftell F. 2001. The pathophysiology of migraine. The Neurologist, 7:279-286.
88. Tepper SJ, Dahlof CGH, Dowson A, et al. 2004. Prevalence and diagnosis of migraine patients consulting their physician with a complaint of headache: data from the Landmark study. Headache, 44:856-864.
89. The International Classification of Headache Disorders 2nd edition. 2004. Cephalagia, 24(Suppl 1):1-160.
90. Thomsen LL, Olesen J. 2004. Sporadic hemiplegic migraine. Cephalagia, 24:1016-23.
91. Villalón CM, Centurion D, Valdivia LF, et al. 2003. Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol, 1:71-84.
92. Waeber C, Moskowitz M. 2005. Migraine as an inflammatory disorder. Neurology, 64(Suppl.2):S9-S15.
93. Weiller C, May A, Limmroth V, et al. 1995. Brainstem activation in spontaneous human migraine attacks. Nat Med, 1:658-60.
94. Welch KM, Nagesh V, Aurora SK, et al. 2001. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache, 41:629-37.
95. Welch KMA. 2003. Contemporary concepts of migraine pathogenesis. Neurology, 61(Suppl 4):S2-S8.